DESTINY-Lung04 — 1L trastuzumab deruxtecan in HER2-mutant NSCLC
HARMONi-2 — ivonescimab vs pembrolizumab in 1L PD-L1-positive advanced NSCLC
REZILIENT 3 — zipalertinib + chemotherapy in EGFR exon 20 insertion NSCLC
PAPILLON — final OS with amivantamab + chemotherapy in EGFR exon 20 insertion NSCLC
ADAURA — 8-year update of adjuvant osimertinib
ARROS-1 — zidesamtinib in…
